A first-in-human study of the novel HIV-fusion inhibitor C34-PEG<sub>4</sub>-Chol.

Although a highly significant drop in HIV RNA of −3.10 Log 10 was observed on day 4 after administration of 20 mg to participant 5, review of pre-study HIV RNA levels suggested a lower set-point HIV RNA load was normal for this participant thus mitigating the magnitude of the observed antiviral effect in this participant.

also in 132,142 other papers